Cheolhee Won, Byung‐Hak Kim, Eun Hee Yi, Kyung‐Ju Choi, Eun‐Kyung Kim, Jong‐Min Jeong, Jae‐Ho Lee, Ja‐June Jang, Jung‐Hwan Yoon, Won‐Il Jeong, In‐Chul Park, Tae Woo Kim, Sun Sik Bae, Valentina M. Factor, Stephanie Ma, Snorri S. Thorgeirsson, Yun‐Han Lee, Sang‐Kyu Ye – 6 July 2015 – Enhanced expression of the cancer stem cell (CSC) marker, CD133, is closely associated with a higher rate of tumor formation and poor prognosis in hepatocellular carcinoma (HCC) patients.

Catherine de Martel, Delphine Maucort‐Boulch, Martyn Plummer, Silvia Franceschi – 3 July 2015 – Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of hepatocellular carcinoma (HCC). In order to assess the relative contribution of HBV and HCV to HCC worldwide, and identify changes over time, we conducted a systematic review of case series published up to the year 2014. Eligible studies had to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti‐HCV), alone and in combination, for at least 20 adult HCC cases.

Laura Kulik, Riad Salem – 3 July 2015

Hiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues, Fumitaka Suzuki, Kenji Ikeda, Hidenori Toyoda, Ken Sato, Yoshiyasu Karino, Yasushi Matsuzaki, Kiyohide Kioka, Carolyn Setze, Tami Pilot‐Matias, Meenal Patwardhan, Regis A. Vilchez, Margaret Burroughs, Rebecca Redman – 3 July 2015 – GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b–infected patients.

Aaron F. Carlin, Paula Aristizabal, Qinghua Song, Huan Wang, Matthew S. Paulson, Luisa M. Stamm, Robert T. Schooley, David L. Wyles – 3 July 2015 – The analysis of inflammatory cytokines and chemokines produced during hepatitis C virus (HCV) infection has advanced our understanding of viral‐host interactions and identified predictors of treatment response. Administration of interferons (IFNs) made it difficult to interpret biomarkers of immune activation during treatment. Direct‐acting antiviral (DAA) regimens without IFN are now being used to treat HCV with excellent efficacy.

Stuart J. Forbes – 3 July 2015

Catherine de Martel, Delphine Maucort‐Boulch, Martyn Plummer, Silvia Franceschi – 3 July 2015 – Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of hepatocellular carcinoma (HCC). In order to assess the relative contribution of HBV and HCV to HCC worldwide, and identify changes over time, we conducted a systematic review of case series published up to the year 2014. Eligible studies had to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti‐HCV), alone and in combination, for at least 20 adult HCC cases.

Mohsen Hasanin, Derek A. Dubay, Brendan M. McGuire, Thomas Schiano, Ashwani K. Singal – 1 July 2015

Marcus R. Pereira, Brendan F. Scully, Stephanie M. Pouch, Anne‐Catrin Uhlemann, Stella Goudie, Jean E. Emond, Elizabeth C. Verna – 1 July 2015 – Carbapenem‐resistant Klebsiella pneumoniae (CRKP) infection is increasing in incidence and is associated with increased mortality in liver transplantation (LT) recipients. We performed a retrospective cohort study of all patients transplanted between January 2010 and January 2013 to identify the incidence and risk factors for post‐LT CRKP infection and evaluate the impact of this infection on outcomes in a CRKP‐endemic area.

Raymond Kwan, Lu Chen, Koksun Looi, Guo‐Zhong Tao, Sujith V. Weerasinghe, Natasha T. Snider, Mary Anne Conti, Robert S. Adelstein, Qing Xie, M. Bishr Omary – 30 June 2015 – Keratins, among other cytoskeletal intermediate filament proteins, are mutated at a highly conserved arginine with consequent severe disease phenotypes due to disruption of keratin filament organization.